Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast...
First-in-class multimodal immunotherapy candidate, for induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid tumors...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader...
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted...
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of...
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin...
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused,...
TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
LUND, SE / ACCESSWIRE / April 8, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented new...
Halifax, Nova Scotia--(Newsfile Corp. - April 8, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")...
Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrheaSAN FRANCISCO,...
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of...
Live webcast with members of the Autonomix management team, on Thursday, April 11th at 12:00 PM ET THE WOODLANDS, TX,...
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity...
WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that...
CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company,...
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca...
In combination with either atezolizumab or durvalumabMADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...